Difference between revisions of "Team:ETH Zurich"

Revision as of 14:39, 7 October 2017

Cancer kills over 8 million people every year. That's the entire population of Switzerland!

We need more specific therapies because current approaches result in many side-effects.
That's why we created CATE: Cancer-Targeting E. coli.

Learn more

CATE consists of the non-pathogenic bacterium E. coli Nissle that has the intrinsic ability to home specifically in tumors.

We are engineering E. coli Nissle to carry a MRI contrast and a cytotoxic agent so it can deliver both components to tumor sites.

Project description

@@ Line 67: / Line 67: @@
      color: #202020;
      line-height: 130%;
+    padding-bottom: 50px;
 }